Navigation Links
Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
Date:10/7/2009

elected to the National Academy of Sciences in 1990. In 2001, Dr. Steitz together with Drs. Moore and Noller received the Rosenstiel Award for Distinguished Work in Basic Medical Sciences for their research on the ribosome. Currently, Dr. Steitz is the Sterling Professor of Molecular Biophysics and Biochemistry and a Howard Hughes Medical Institute Investigator at Yale University. His research in the field of protein and nucleic acid X-ray crystallography, including his recent work with Dr. Moore on the 50S ribosome structure has had wide-ranging impact in the global scientific community.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics, including radezolid, that can be used for the treatment of either community- or hospital-acquired infections. Delafloxacin (RX-3341) is a Phase 3-ready broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including methicillin-resistant S. aureus. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X as an oral/IV agent for treatment of serious Gram-positive infections, has completed two Phase 2 trials. The Rx-04 discovery progra
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... SPARTANBURG, South Carolina , May 29, ... and Molecular Health have announced a collaboration designed to ... support to the majority of cancer patients living in ... collaborate with Molecular Health to harness the power of ... from hundreds of thousands of patients to enable ,accrual ...
(Date:5/29/2015)... , May 29, 2015  Haemonetics Corporation (NYSE: ... , Chief Operating Officer, will present at the JMP ... on June 23 rd , 2015 at ... access Mr. Davies, presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
(Date:5/29/2015)... 2015  World-renowned prostate surgeon and New York Urologist, Dr. ... of MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive ... Center at Lenox Hill Hospital is the only center ... New York City . We,ve seen tremendous improvement ... The use of an MRI makes for a much more ...
Breaking Medicine Technology:New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... FRANCISCO, Nov. 7 Epiphany Biosciences announced,today that ... 2b clinical trial with,valomaciclovir (EPB-348) for the treatment ... a highly potent anti-viral with enhanced,delivery and bioavailability. ... an important milestone in,our development of valomaciclovir," said ...
... in Watt Poultry USA states that acidic treatments benefit poultry ... ... FreshFx Antimicrobial Solution,which is used to reduce pathogens during poultry processing, ... to solve the,"yield/pathogen reduction dilemma." Citing recent studies in large-scale ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles 2FreshFx Recognized for use in the Scalder as a Solution to the 'Yield/Pathogen Reduction Dilemma' 2
(Date:5/30/2015)... (PRWEB) May 30, 2015 One of ... lack of local healthcare options available. Often, the ruralness ... healthcare. For those in rural areas feeling the crunch ... health insurance or tired of paying high premiums and ... connecting patients with licensed physicians via the power of ...
(Date:5/30/2015)... New York, New York (PRWEB) May 30, 2015 ... ordered to pay $100 million in punitive and ... http://www.vaginalmeshlawsuit2015.com/ ) plaintiff who suffered serious complications following ... devices. According to a verdict rendered on May ... awarded $25 million in compensatory damages after the ...
(Date:5/30/2015)... May 30, 2015 EHO offers a ... Portal that gives hospices the ability to manage their ... of this business model, EHO has been able to ... to its clients and survive among the giants of ... management systems three years ago, it has simplified the ...
(Date:5/30/2015)... Nicole Blodgett, Vice President of Secura ... designation to further her expertise in the income ... insurance advisors, health care professionals, and financial planners ... associated with the risk and the cost with ... the latest accomplishment in Nicole's journey with Secura ...
(Date:5/30/2015)... 2015 The Brain Fitness Education seminar ... ONEgeneration Senior Enrichment Center, headed by 1Heart Client Care ... and Brain Fitness Program Director Tee Barr. , Senior ... that there are many ways to enrich and further ... residents the different ways to overcome dementia and memory ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3
... Informatics is hosting a meeting that is to discuss ... health records. The first meeting on Personally Controlled Health ... 10-11. // ,"The work done at this ... of healthcare information infrastructure," said keynote speaker Mitch Kapor, ...
... of four counts of misconduct. ,The doctor failed ... mother of three children. She died on February 2003 of ... constipation for more than a year. The doctor is accused ... another GP, not referring her to another specialist and failing ...
... bacteria and combinations of bacteria could explain the relationship ... to a new study published in the Journal of ... was two times higher in the ACS group for ... T. forsythia and T. denticola. Specifically, the findings suggest ...
... are concerned that children in primary schools have become ... tackle inappropriate// sexual behaviour. ,Children as young ... a rather "sexualised" manner with games such as kiss ... to set alarm bells ringing. ,Reports from ...
... enzyme found in the venom of the brown recluse spider, ... discovered a new way to open// molecular pores, called ion ... research team – Zhe Lu, MD, PhD; Yajamana Ramu, PhD; ... at Penn – screened venoms from over 100 poisonous invertebrate ...
... new vision correction technology, Zyoptix Aspheric, which reduces post-Lasik ... clinics all across India which use Zyoptix technology to ... Zyoptix Aspherix which further reduces post Lasik surgery glare, ... Director-Surgical business Rajat Goel told reporters here., ,The ...
Cached Medicine News:Health News:Meeting To Discuss Issue Of Personal Health Records 2Health News:Meeting To Discuss Issue Of Personal Health Records 3Health News:Link between Periodontal Bacteria and Heart Disease Established 2Health News:New Way to Open Cellular Ion Channels, Implications for Drug Design 2
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
Coaxial fiberoptic headlight has fixed spot size of 120mm. It weighs only 4.5 ounces....
View Mex-2 is designed for out-patient surgery, hospital rounds and house calls....
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband....
Medicine Products: